The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Anitocabtagene autoleucel (anito-cel) clinical trial manufacturing experience in patients with relapsed/refractory (RR) or newly diagnosed (ND) multiple myeloma (MM).
 
Krina Patel
Leadership - Bristol-Myers Squibb/Celgene; Kite, a Gilead company; oricel
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Celgene; Janssen; Legend Biotech; Merck; Novartis; Pfizer; Regeneron; Takeda
Research Funding - Abbvie/Genentech; Celgene/Bristol-Myers Squibb; Indapta Therapeutics; Janssen; Nektar
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Clare Spooner
Employment - Kite, a Gilead Company
Stock and Other Ownership Interests - Gilead Sciences
 
Monique Giordana
Employment - Kite, a Gilead Company
Stock and Other Ownership Interests - Gilead Sciences
 
Taryn Shuler
Employment - Kite, a Gilead Company
Stock and Other Ownership Interests - Gilead Sciences
 
David Myers
Employment - Kite, a Gilead Company
Stock and Other Ownership Interests - Gilead Sciences
Travel, Accommodations, Expenses - Kite, a Gilead Company
 
María-Victoria Mateos
Honoraria - Abbvie/Genentech; Amgen; Celgene; GlaxoSmithKline; Janssen-Cilag; Pfizer; Sanofi
Consulting or Advisory Role - Abbvie; Amgen; Celgene; GlaxoSmithKline; Janssen-Cilag; Kite, a Gilead company; Pfizer; Regeneron; Roche/Genentech; Stemline Therapeutics; Takeda